{
  "documentMetadata": {
    "title": "Babesiosis",
    "lastUpdated": "2024-09-26",
    "sourceFile": "Babesiosis.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 2,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Tick-borne and transfusion-associated disease; congenital infection also reported. Review: [N Engl J Med 366:2397, 2012](https://www.nejm.org/doi/full/10.1056/NEJMra1110910).",
        "Tick vector for Babesia microti is Ixodes scapularis. Reservoir host is the white-footed mouse (and others). See Tick-borne Illness, Overview.",
        "B. microti is a blood safety issue with >200 transfusion-transmissions reported ([Transfusion 59; 2908, 2019](https://onlinelibrary.wiley.com/doi/10.1111/trf.15452)).",
        "Since 2019, FDA requires Babesia testing of red blood cell products in 15 high-risk states",
        "Lyme disease and human granulocytic anaplasmosis have the same tick vector and reservoir host as Babesia microti.",
        "Most U.S. tick-borne cases are in the Mid-Atlantic, Northeast and upper Midwest. Sporadic Babesia cases caused by novel agents have been identified in various parts of the U.S.",
        "Babesia parasites infect the red blood cells of the host. Symptoms result from hemolysis.",
        "Asymptomatic infection typically does not need to be treated.",
        "Most patients are older males during June-August; overall mortality 1.6%.",
        "Babesiosis can be fatal in asplenic and immunocompromised patients, [Clin Infect Dis 46:370, 2008](https://academic.oup.com/cid/article/46/3/370/318189). Risk factors for severe disease: over age 60, rituximab use, thrombocytopenia, parasitemia >10%.",
        "If severe or persistent symptoms despite appropriate therapy for babesiosis, consider co-infection with the etiologic agents of Lyme Disease or human anaplasmosis.",
        "Clinical practice guidelines: [Clin Infect Dis 72:185, 2021](https://academic.oup.com/cid/article/72/2/185/5895495)."
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Diagnosis"
    },
    {
      "type": "list",
      "items": [
        "Examine stained smear of peripheral blood.",
        "PCR detection where/when available",
        "Serology no longer recommended; may indicate previous infection",
        "Note: molecular and serologic testing for B. microti does not detect other agents/species"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Babesia microti (U.S.)",
        "Babesia duncani (Western U.S.)",
        "Babesia divergens (almost all infections in Europe: [Pathogens 2023;12:323](https://www.mdpi.com/2076-0817/12/2/323))",
        "Babesia motasi (Korea, China)"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "Asymptomatic disease in healthy host with intact spleen.\nNo treatment",
        "Adult mild/moderate disease (outpatient, <4% parasitemia).\n[(Atovaquone 750 mg po q12h) + (Azithromycin 500 mg po on day 1, then 250 mg/day po)] for a total of 7-10 days.",
        "Acute severe disease (hospitalized)\nAdult: Atovaquone 750 mg po q12h + Azithromycin 500-1000 mg IV q24h until symptoms abate, then convert to all oral step-down therapy\nFollow with step-down therapy: Atovaquone 750 mg po q12h + Azithromycin 250â€“500 (500-1000 if immunocompromised) mg po q24h to complete a total of 7-10 days.",
        "Highly Immunocompromised patients:\nTreat for 6 consecutive weeks with a regimen as per severe disease ensuring negative blood smears for the final 2 weeks.\nReview of treatment in this population: [Curr Opin Infect Dis 2024 Oct 1;37(5):327](https://journals.lww.com/co-infectiousdiseases/abstract/2024/10000/treatment_of_babesiosis__a_moving_target.6.aspx).",
        "Consider exchange transfusion for patients with parasitemia >10% or moderate to high-grade parasitemia any of: severe hemolytic anemia or pulmonary, renal, or hepatic compromise.",
        "Pediatric doses: Atovaquone 20 mg/kg per dose po; Azithromycin 10 mg/kg IV/po according to adult schedules/routes above except 5 mg/kg po after initial dose in mild/moderate cases.\nNever exceed adult dose\nAtovaquone/azithromycin recommended but no clinical trials with severe babesiosis"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "Clindamycin + quinine is preferred in pregnant women and when parasitemia and symptoms have failed to abate following initiation of Atovaquone + Azithromycin.",
        "Mild/moderate: Clindamycin 600 mg po q8h + quinine sulfate 542 mg base (which equals 650 mg salt) po q6h-8h x 7 to 10 days.",
        "Acute Severe Hospitalized: Clindamycin 600 mg IV q6h + quinine sulfate 542 mg base po q6h-8h until symptoms abate, then convert to all oral step-down therapy.\nFollow with step-down therapy: Clindamycin 600 mg po q8h + quinine sulfate 542 mg base po q6h-8h to complete a total of 7-10 days",
        "Pediatric doses: Clindamycin 7-10 mg/kg po q8h; quinine sulfate 6 mg base/kg (which equals 8 mg salt/kg) according to adult schedules/routes above. Never exceed adult dose.",
        "For treatment failures or relapses consider following combinations:\nAtovaquone + Azithromycin + Clindamycin;\nAtovaquone + Clindamycin;\nAtovaquone/proguanil + Azithromycin;\nAtovaquone + Azithromycin + Clindamycin + quinine. Use 500-1000 mg of Azithromycin."
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Monitor blood smears in immunocompetent during acute symptoms only and till blood smears clear if immunocompromised.",
        "No available antibiotic prophylaxis",
        "in vivo animal data for efficacy of tafenoquine ([J Infect Dis 220:442, 2019](https://academic.oup.com/jid/article/220/3/442/5365585))",
        "Relapse in single highly compromised patient after 6 weeks of tafenoquine ([Pathogens 2022 Sep 15;11(9):1051](https://www.mdpi.com/2076-0817/11/9/1051)).",
        "Triple therapy with tafenoquine-atovaquone-azithromycin for 10 days vs atovaquone-azithromycin under investigation in severe hospitalized cases ([J Infect Dis 2024 May 15;229(5):1599](https://academic.oup.com/jid/article/229/5/1599/7670297)).",
        "Weekly tafenoquine maintenance after relapse in immunocompromised patients ([Clin Infect Dis 2024 Jul 19;79(1):130](https://academic.oup.com/cid/article/79/1/130/7670296)).",
        "Comprehensive review: [Infect Dis Clin North Am 2022 Sep;36(3):655](https://www.sciencedirect.com/science/article/pii/S089155202200034X)",
        "B. motasi only a few human cases so far.",
        "Seven tropical infections were pathogen visible in peripheral blood smear: African/American trypanosomiasis, babesia, bartonellosis, filariasis, malaria, relapsing fever."
      ]
    }
  ]
}